Fed. Circ. Mulls Undoing Mylan Win In Biogen Drug IP Fight
Two Federal Circuit judges on Tuesday suggested that a Mylan attorney's argument that a Biogen patent on multiple sclerosis drug Tecfidera failed to disclose the efficacy of a specific dosage is...To view the full article, register now.
Already a subscriber? Click here to view full article